I-SPY2 Participant Information
Widely hailed as the future of phase II drug development, the adaptive I-SPY 2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
Please see the attached message regarding the COVID-19 pandemic for patients enrolled in the I-SPY2 trial.
If you have any questions or concerns, please contact your clinical coordinator.
pdf download
Dr. Laura Esserman discusses "How to think about your cancer care in the time of COVID-19" for Time magazine.
view video and article
Learn about the I-SPY2 Trial from our subject matter experts
Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.
